Hill-Rom (NYSE:HRC) Price Target Raised to $125.00

Share on StockTwits

Hill-Rom (NYSE:HRC) had its price objective lifted by KeyCorp from $114.00 to $125.00 in a research report report published on Monday morning, BenzingaRatingsTable reports. KeyCorp currently has an overweight rating on the medical technology company’s stock. KeyCorp also issued estimates for Hill-Rom’s FY2021 earnings at $6.25 EPS.

HRC has been the topic of several other reports. Zacks Investment Research raised Hill-Rom from a hold rating to a buy rating and set a $103.00 target price on the stock in a research report on Thursday, June 6th. Barclays increased their target price on Hill-Rom from $103.00 to $108.00 and gave the stock an equal weight rating in a research report on Monday, April 15th. Finally, ValuEngine lowered Hill-Rom from a buy rating to a hold rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Hill-Rom has an average rating of Buy and an average target price of $112.43.

Shares of HRC opened at $104.10 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.51 and a debt-to-equity ratio of 1.12. The stock has a market cap of $6.69 billion, a price-to-earnings ratio of 19.93, a P/E/G ratio of 1.73 and a beta of 0.90. The business has a fifty day moving average price of $105.23. Hill-Rom has a twelve month low of $81.82 and a twelve month high of $109.18.

Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, August 2nd. The medical technology company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.02. The business had revenue of $726.80 million for the quarter, compared to analyst estimates of $718.08 million. Hill-Rom had a return on equity of 21.26% and a net margin of 7.45%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the company posted $1.15 EPS. On average, equities research analysts forecast that Hill-Rom will post 5.05 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Friday, September 20th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.81%. The ex-dividend date is Thursday, September 19th. Hill-Rom’s dividend payout ratio (DPR) is presently 17.68%.

A number of large investors have recently added to or reduced their stakes in the business. Litman Gregory Asset Management LLC acquired a new position in Hill-Rom in the second quarter worth about $26,000. Hanseatic Management Services Inc. acquired a new position in Hill-Rom in the first quarter worth about $30,000. Sageworth Trust Co acquired a new position in Hill-Rom in the first quarter worth about $32,000. Tortoise Investment Management LLC acquired a new position in Hill-Rom in the second quarter worth about $31,000. Finally, TRUE Private Wealth Advisors acquired a new position in Hill-Rom in the second quarter worth about $38,000. 81.52% of the stock is currently owned by institutional investors.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

See Also: Should I follow buy, hold and sell recommendations?

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BlackRock TCP Capital  Upgraded at BidaskClub
BlackRock TCP Capital Upgraded at BidaskClub
SSR Mining  Lowered to Hold at BidaskClub
SSR Mining Lowered to Hold at BidaskClub
SVB Financial Group  Receives “Buy” Rating from Stephens
SVB Financial Group Receives “Buy” Rating from Stephens
Zacks Investment Research Upgrades Churchill Downs  to “Hold”
Zacks Investment Research Upgrades Churchill Downs to “Hold”
Baozun  Upgraded at BidaskClub
Baozun Upgraded at BidaskClub
Apollo Endosurgery  Downgraded by Zacks Investment Research
Apollo Endosurgery Downgraded by Zacks Investment Research


 
© 2006-2019 Zolmax.